SCHEMBL1362228

SCHEMBL1362228

Clc1cccc(Cl)c1CNc1nc2ccccc2[nH]1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.65
SMN1; SMN2 Q16637 3/20 0.65
TP53 P04637 1/20 0.65
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
GFER P55789 1/20 0.60
ALDH1A1 P00352 3/20 0.56
BCHE P06276 1/20 0.54
TRPC3 Q13507 1/20 0.54
TRPC4 Q9UBN4 1/20 0.54
TRPC5 Q9UL62 1/20 0.54
PKM P14618 2/20 0.51
NPC1 O15118 4/20 0.50
GAA P10253 2/20 0.50
LMNA P02545 2/20 0.50
TSHR P16473 1/20 0.48
KDM4E B2RXH2 2/20 0.47
GPR55 Q9Y2T6 1/20 0.47
MAPT P10636 2/20 0.47
HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1360590 0.98 RAB9A (0.63) RAB9ASMN1; SMN2TP53MEN1KMT2A
SCHEMBL1361952 0.87 BCHE (0.57) RAB9ASMN1; SMN2TP53MEN1KMT2A
SCHEMBL31329349 0.86 MEN1 (0.66) RAB9ASMN1; SMN2TP53MEN1KMT2A
SCHEMBL28801773 0.86 MEN1 (0.66) RAB9ASMN1; SMN2TP53MEN1KMT2A
SCHEMBL31329347 0.80 RAB9A (0.77) RAB9ASMN1; SMN2TP53MEN1KMT2A
SCHEMBL27915820 0.80 RAB9A (0.77) RAB9ASMN1; SMN2TP53MEN1KMT2A
SCHEMBL12658352 0.80 RAB9A (0.67) RAB9ASMN1; SMN2TP53MEN1KMT2A
SCHEMBL31329338 0.80 RAB9A (0.71) RAB9ASMN1; SMN2TP53MEN1KMT2A
SCHEMBL31329340 0.79 RAB9A (1.00) RAB9ASMN1; SMN2TP53MEN1KMT2A
SCHEMBL3593419 0.79 RAB9A (1.00) RAB9ASMN1; SMN2TP53MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100168196-A1 N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-07-01 US claimed
US-20080167359-A1 N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-07-10 US claimed
EP-1592671-B1 N-SUBSTITUTED (BENZOIMIDAZOLE-2-YL) PHENYL AMINES, METHOD FOR THEIR PRODUCTION, THEIR USE AS A MEDICAMENT OR DIAGNOSTIC AGENT AND MEDICAMENT CONTAINING SAID SUBSTANCES SANOFI AVENTIS DEUTSCHLAND (DE) 2008-04-09 EP claimed
US-20050054705-A1 N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-03-10 US claimed
US-8067614-B2 N-substituted (benzoimidazol-2-yl)phenylamines, processes for their preparation, their use as a medicament or diagnostic aid, and a medicament comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-11-29 US disclosed
US-20100168196-A1 N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-07-01 US disclosed
US-20080167359-A1 N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-07-10 US disclosed
EP-1592671-B1 N-SUBSTITUTED (BENZOIMIDAZOLE-2-YL) PHENYL AMINES, METHOD FOR THEIR PRODUCTION, THEIR USE AS A MEDICAMENT OR DIAGNOSTIC AGENT AND MEDICAMENT CONTAINING SAID SUBSTANCES SANOFI AVENTIS DEUTSCHLAND (DE) 2008-04-09 EP disclosed
EP-1592671-A1 N-SUBSTITUTED (BENZOIMIDAZOLE-2-YL) PHENYL AMINES, METHOD FOR THEIR PRODUCTION, THEIR USE AS A MEDICAMENT OR DIAGNOSTIC AGENT AND MEDICAMENT CONTAINING SAID SUBSTANCES Sanofi-Aventis Deutschland GmbH (DE) 2005-11-09 EP disclosed
US-20050054705-A1 N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-03-10 US disclosed
WO-2004069811-A1 N-SUBSTITUTED (BENZOIMIDAZOLE-2-YL) PHENYL AMINES, METHOD FOR THEIR PRODUCTION, THEIR USE AS A MEDICAMENT OR DIAGNOSTIC AGENT AND MEDICAMENT CONTAINING SAID SUBSTANCES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167359-A1 N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them SLC10A1, SLC9A3, ABCB11 RAB9A 2051/4885SMN1; SMN2 674/4885TP53 4824/4885
US-20100168196-A1 N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them SLC10A1, SLC9A3, ABCB11 RAB9A 2051/4885SMN1; SMN2 674/4885TP53 4824/4885
US-20050054705-A1 N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them SLC10A1, SLC9A3, NHERF1 RAB9A 1936/4885SMN1; SMN2 651/4885TP53 4830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.